
Calidi Biotherapeutics Inc. Receives FDA Fast Track Designation for CLD-201 in Soft Tissue Sarcoma
Calidi Biotherapeutics Inc. has been granted FDA Fast Track designation for CLD-201, a promising treatment for soft tissue sarcoma, marking a significant step forward in the development of targeted genetic medicine delivery therapies.
Read full story


























